Researchers Identify New Driver of Gastric Cancer Spread
A specific genetic signaling axis has been found to promote lymphatic metastasis in patients with gastric cancer.
Updated on Oct. 15, 2026 in Cancer
Scientists have identified the IGF2BP1-METTL21A-SOX18-CXCL12 signaling axis as a primary driver of lymphatic metastasis in gastric cancer. This pathway facilitates the spread of cancer cells by enhancing lymphangiogenesis.
Why it matters
Understanding this signaling pathway offers a potential new therapeutic target for preventing the lymphatic spread of gastric cancer. Targeting these specific proteins could limit the ability of the cancer to metastasize in patients.
The study confirmed that IGF2BP1 is upregulated in cancer tissues with lymph node metastasis. Researchers established that METTL21A knockout and SOX18 depletion effectively abolish IGF2BP1-induced lymphangiogenesis.
The players
IGF2BP1
This is an RNA-binding protein that acts as an oncogene by stabilizing specific mRNA transcripts to promote tumor progression.
METTL21A
This protein functions as a non-histone lysine methyltransferase that modifies transcription factors to regulate gene expression.
SOX18
This transcription factor plays a critical role in developmental processes and the regulation of lymphangiogenesis.
CXCL12
This is a chemokine that binds to the CXCR4 receptor to facilitate cell migration and the development of lymphatic vessels.
The details
The process begins with the upregulation of IGF2BP1, which stabilizes METTL21A mRNA to boost its expression. METTL21A then methylates the transcription factor SOX18, allowing it to enter the nucleus and activate CXCL12, which subsequently promotes the formation of new lymphatic vessels through CXCR4 signaling.
Timeline
The research findings were officially published on October 15, 2026.
The Big Picture
This discovery updates the existing understanding of how the m6A RNA modification landscape influences cancer progression. By identifying a specific signaling axis, the study provides a new theoretical framework for how RNA-binding proteins orchestrate complex metastatic behaviors.
While this discovery provides a new target for drug development, it does not currently change existing treatment protocols for patients. Future therapies resulting from this research may eventually offer more precise options to prevent cancer from spreading to the lymph nodes.
The takeaway
This study marks a significant step forward in mapping the complex molecular drivers of gastric cancer spread. Scientists believe that inhibiting the identified signaling pathway could eventually provide a strategy to block metastasis at the source.
Further reading
For more information on current oncology breakthroughs, visit the Cancer section.
Source note: This article includes information reported by Nature.
